Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Parallel Treatment Group, Phase 2a, Double-blind, 4-arm Trial to Evaluate the Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Male and Female Participants Aged 30 Years or Older With Metabolic Dysfunction-associated Steatohepatitis (MASH)

NCT07491458 is registered in ClinicalTrials.gov with Rivus Pharmaceuticals, Inc. as lead sponsor.

NCT NCT07491458
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07491458 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Parallel Treatment Group, Phase 2a, Double-blind, 4-arm Trial to Evaluate the Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Male and Female Participants Aged 30 Years or Older With Metabolic Dysfunction-associated Steatohepatitis (MASH)
Lead sponsor
Rivus Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
February 13, 2026
Completion date
February 29, 2028
Enrollment
180 (estimated)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

mash - metabolic dysfunction-associated steatohepatitis